Balaxi Pharmaceuticals Ltd (BALAXI)

Healthcare · Pharmaceuticals · NSE · Updated 3 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

🎯 Key Takeaways

Balaxi Pharmaceuticals is in a strategic transition phase, shifting from a domestic-focused entity to a backward-integrated manufacturer targeting frontier markets in Latin America and Africa. The company has commenced commercial production at its new formulation facility in Hyderabad, aiming to enhance margins through cost control and vertical integration.
Revenue grew 14.1% QoQ to ₹81 in Q1FY27.
⚠️ The company's profitability remains highly sensitive to margin improvements from the new Hyderabad facility, which has just commenced commercial produ

ROE

1.1%

ROCE

3.6%

Debt/Equity

0.22

Promoter

66.0%

✨ Ask AI About BALAXI 📊 Interactive Charts

📖 The Story

Balaxi Pharmaceuticals is in a strategic transition phase, shifting from a domestic-focused entity to a backward-integrated manufacturer targeting frontier markets in Latin America and Africa. The company has commenced commercial production at its new formulation facility in Hyderabad, aiming to enhance margins through cost control and vertical integration. Despite low profitability metrics (ROE: 1.1%, ROCE: 3.6%), recent financials show improving operational efficiency and profitability, driven by margin expansion and scale in new markets.

📰 What's Happening

In Q1 FY27, Balaxi reported consolidated revenue of ₹80.68 crore, up 14% YoY, with PAT surging 347% to ₹1.29 crore, supported by a 241 bps gross margin expansion to 46.5%. The company achieved a key milestone with commercial production at its Hyderabad facility, targeting backward integration in Latin America and Africa. Management highlighted that operating leverage from this expansion should further improve profitability. Corrections were made to prior XBRL filings for expense and comprehensive income figures, but no operational changes were introduced. The 83rd AGM approved financial statements and reappointed key directors, reinforcing leadership stability. The BRSR report confirmed export-driven operations and ESG compliance but disclosed no financial performance targets.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	56	73	71	81
Operating Profit	1	3	-1	4
OPM %	1.2%	3.5%	-0.7%	4.7%
Net Profit	0	0	1	1
EPS	₹0.04	₹0.06	₹0.11	₹0.24

Revenue has shown consistent growth, rising from ₹56 crore in September 2025 to ₹80.68 crore in June 2026, reflecting expanding market traction. Operating performance improved significantly, with OPM increasing from 1.2% to 4.7% and PAT turning positive after years of losses. The shift from minor losses in Q3 and December 2025 to ₹1.29 crore PAT in Q1 FY27 indicates early success from the Hyderabad facility's commercial operations. This margin expansion aligns with management's guidance on profitability improvement through operating leverage.

🔮 Management Outlook & What's Next

Management expects further profitability improvement as operating leverage strengthens from the Hyderabad facility's commercial production. The company is focused on expanding its footprint in frontier markets through new product registrations and geographic presence. No specific forward guidance on revenue or margins was provided in the latest filings, but the transition to backward integration is positioned as a core growth driver. Management emphasized compliance and audit validation of international subsidiary financials as part of governance rigor.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	11	11	11	11
Reserves	205	221	227	238
Borrowings	32	52	57	58
Total Liabilities	288	310	322	337
Fixed Assets	17	41	13	49
Investments	0	0	0	0
Total Assets	288	310	322	337

The balance sheet shows stable equity of ₹11 crore and modest growth in reserves from ₹221 to ₹238 crore, indicating conservative capital accumulation. Borrowings remain low at ₹57-58 crore, suggesting minimal debt reliance. Total assets grew from ₹310 to ₹337 crore, reflecting investments in infrastructure, likely tied to the new facility. The asset-light model and lack of manufacturing CAPEX, as noted in the BRSR, imply capital efficiency, with growth likely funded through internal cash flows or minimal external financing.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	-35
Investing	-22
Financing	+34
Net Cash Flow	-23

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	66.0%	66.0%	66.0%	66.0%
FII	3.5%	1.7%	0.0%	0.0%
DII	0.0%	0.0%	2.6%	2.6%
Public	20.0%	22.4%	24.4%	24.4%
# Shareholders	14,620	15,085	15,176	14,682

Promoter holding remains stable at 65.99%, indicating confidence. FII allocation is negligible at 0%, while DII holding is minimal at 2.56%, suggesting limited institutional interest. Public shareholding has slightly increased, with the number of shareholders rising from 14,620 to 15,176, indicating retail investor engagement. No significant buying or selling by FII/DII is evident, and no pledging or exit signals were disclosed. The shareholder base remains stable with incremental retail participation.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.64 L Cr	38.4	18.7%	14.6%	0.05
DIVISLAB	2.45 L Cr	83.8	23.0%	17.4%	0.00
TORNTPHARM	1.90 L Cr	79.8	15.1%	25.7%	1.76
ZYDUSLIFE	1.15 L Cr	25.7	16.8%	16.6%	0.43
CIPLA	1.14 L Cr	33.9	13.2%	9.8%	0.01
LAURUSLABS	1.01 L Cr	92.0	20.8%	20.6%	0.45
LUPIN	98,424	17.4	27.9%	24.7%	0.26
MANKIND	98,293	48.1	13.9%	12.7%	0.38
DRREDDY	96,906	30.0	10.1%	8.4%	0.17
AUROPHARMA	95,300	25.9	12.8%	9.8%	0.20

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. The company's profitability remains highly sensitive to margin improvements from the new Hyderabad facility, which has just commenced commercial production. 2. Exposure to international markets in Latin America and Africa introduces currency, regulatory, and geopolitical risks. 3. The asset-light model and reliance on subsidiaries, including one in Dubai with reported net losses, may pressure overall group profitability. 4. Low ROE and ROCE indicate challenges in generating returns on capital, which may limit investor appeal despite operational progress.

📋 Recent Filings

🧠 Analyst's Read

Balaxi Pharmaceuticals is executing a clear strategic shift toward backward integration and frontier market expansion, supported by early signs of margin improvement and revenue growth. The company's financial trajectory suggests progress, but profitability remains nascent and concentrated in new ventures. Investors should monitor execution risks in international markets and the scalability of the Hyderabad facility's operations in the coming quarters.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on BALAXI

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-03.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when BALAXI files new disclosures

Track BALAXI filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track BALAXI — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd